Cell Signaling Technology (CST) has built a diverse team of global executives to advance our global strategic mission: develop the world's highest quality, innovative research, and products to accelerate biological understanding and enable personalized medicine.
“My passion is developing innovative technology to provide insight into disease mechanisms, and, while I act as CEO, I remain the company’s research director in function and in heart.”
Michael leads CST’s efforts to build the best antibody technology in the world for researchers working to understand the molecular and cellular processes of disease. He founded the company to provide the research community with tools that he himself had sought as an investigator.
Before starting CST in 1999, he directed the Molecular Neurobiology Lab at Massachusetts General Hospital and served as an Associate Professor of Neuroscience at Harvard Medical School.
Michael holds a B.S. in chemistry from the University of Massachusetts and a Ph.D. in chemistry from the University of Oregon. He has published more than 60 peer-reviewed scientific articles and is the inventor on numerous patents and patent applications.
“My job is to make sure CST continues to be an organization focused on a very high level of science and innovation.”
Roby drives research, product, and technology innovation, facilitating the creation of CST’s most valuable products, technologies, and intellectual property. Roby has driven the creation and implementation of novel antibody technology platforms that have been critical to CST’s success. He previously served as Director of Research and Vice President for research at CST.
Before joining CST in 1999, he was a staff scientist at the biotechnology company New England Biolabs.
Roby received a B.S. in chemistry and Ph.D. in molecular biology from Hebrew University of Jerusalem, and he has completed postdoctoral studies at the Whitehead Institute for Biomedical Research at M.I.T. He has published approximately 65 peer-reviewed scientific articles and is a named inventor on numerous patents and patent applications.
“I want to grow and transform CST’s global digital capabilities to drive scientific delight in using antibodies to deliver new insights and transform the lives of cancer patients.”
Paul drives the strategic use of technologies at CST. He advances both local and global informatics, supporting IT applications, infrastructure, operations, security, and enterprise architecture. He also manages the approximately 50 employees that make up the IT department.
Before joining CST in 2016, Paul spent more than 20 years in senior research and IT positions. He served as Chief Information Officer for Genomic Health, as Vice President, Global IT, for Biogen Idec, and as Director of DSi for Pfizer.
He has a B.S. in chemistry from California State University, Sacramento, and a Ph.D. in analytical chemistry from the University of Washington. He is also a veteran of the U.S. Coast Guard. He has published more than 40 peer-reviewed scientific articles and is named inventor on three patents.
“A strong financial foundation is essential to fulfilling our commitment to provide the highest quality products and services to the global scientific community. My role is to ensure that we invest responsibly, and maintain our financial strength and independence without sacrificing our core values.”
As the leader of our global finance organization, Matt oversees CST’s accounting, budgeting, forecasting, income tax, treasury and risk management functions. He has also served as CST’s Corporate Controller and Vice President of Finance.
Prior to joining CST in 2006, Matt served as Corporate Controller for Groove Networks, Inc., a software company that Microsoft Corporation acquired in 2005. He played a key role in the company’s early-stage equity financing rounds and, ultimately, the sale of the company to Microsoft Corporation. Earlier in his career, Matt was a Senior Manager with BDO USA LLP, an international accounting firm.
Matt holds a B.A. in Business Administration from St. Anselm College in Manchester, N.H. and is a licensed certified public accountant (CPA) in Massachusetts. He is a member of the American Institute of Certified Public Accountants and the Massachusetts Society of CPA’s.
”We want to continue to build a fantastic culture and make this a really engaging place for our employees to work.”
John oversees all aspects of global human resources at CST to ensure the proper recruitment, development, and retention of the skills and resources necessary to drive the company's mission.
Before joining CST in 2015, John served as Senior Vice President of Human Resources for the biotechnology firm PerkinElmer, Inc., as Director of Human Resources for the engineering company ABB Americas, Inc., as Vice President of Finance for General Ship Corporation, and as a Senior Auditor for Arthur Andersen.
John has a B.S. in accounting and information technology from Boston College.
“I believe in building symbiotic relationships and welcome inquiries from prospective technology, chemistry, platform and content providers.”
Ben oversees the Corporate Development team. The team is responsible for devising and executing CST’s inorganic growth strategy.
Ben began his career in research, studying the mechanisms underlying lung and gastric cancers. After a number of years at the bench, Ben transitioned his thinking from the drivers of cell growth to the drivers of business growth. Ben joined the Corporate Development team at CST as an Analyst and has since served in escalating management roles. Ben received his BS in Biomedical Sciences from the University of California, Santa Barbara, and MS in Biotechnology from the University of Queensland in Australia.
“At CST, my job is to actively participate and contribute to the pursuit of science and real facts.”
Simona leads all CST’s legal matters across the organization, including intellectual property, technology licensing, commercial negotiations and contracting, corporate governance, and corporate and securities law. She also serves as Corporate Secretary on the Board of Directors.
Before joining CST in 2007, Simona spent more than 10 years working as legal counsel for corporate and intellectual property matters in the life sciences industry. She was a partner at the law firm McDermott Will & Emery, served as Director of Neurology for Biogen, as Senior IP Counsel for IVAX corporation, as an Associate and Junior Partner for the law firm Hale and Dorr LLP, and as a technology specialist for the law firm Dann, Dorfman, Herrell and Skimman.
Simona has a B.A. in biochemistry and economics and a Ph.D. in biochemistry from Rutgers University and a J.D. from the University of Pennsylvania Law School. Simona has been a member of the Massachusetts Bar Association since 1995.
“I’m proud to have have helped CST become recognized as the “golden standard” by customers across China and the Asia Pacific region.”
Jay runs CST’s China and Asia Pacific business and organization. He leads a professional teams in marketing, sales, technical support and applications, supply chain management, customer services, logistics and warehouse management, business development, IT, human resources and administration.
Prior to joining CST, Jay was marketing and business leader with Becton Dickinson (BD) Bioscience in the United States and in Singapore. He was an R&D researcher and scientist at Tufts University School of Medicine and Millennium Pharmaceuticals, and a member of the American Association of Immunologists with publications in Journal of Immunology, Infection and Immunity, Journal of Experimental Medicine, and PNAS.
Jay earned an M.B.A. from the Massachusetts Institute of Technology (MIT) Sloan School of Management and an M.A. from Tufts University Fletcher School of Law and Diplomacy, and a Master’s degree from Peking Union Medical College-Tsinghua University Faculty of Medicine.
Jay has been active in serving the communities and has served on a few non-profit Boards of Directors and professional organizations: Board of the BayHelix Group, of the Sino-American Biomedical and Pharmaceutical Professionals Association in the US, and of the Shanghai American School. He received the honor title of Guest Professor from Wuhan University Medical Research Institute and is a Board member of MIT Club of Shanghai.
“My vision for CST is to be a first-class supplier that provides high-quality products and customer service and to continue to be a trusted partner of researchers as they conduct their scientific work.”
Kaz directs sales, marketing, logistics, human resources, general administration, finance, and information technology for CST’s Japanese market. His goals are to increase efficiency, competency, and leadership, and to create a comfortable work environment for CST employees.
Before joining CST in 2015, Kaz spent 10 years in senior positions in a variety of biotechnology companies. He served as General Manager and President of Applied Biosystems Japan Ltd., General Manager and President of Life Technologies Japan Ltd., and as Business Director of BD Biosciences.
“My primary motivator at CST has been to provide CST customers with the most reliable and best-performing products along with outstanding customer support.”
Craig advances manufacturing and distribution for all of CST’s products. He leads the company’s customer service, supply chain management, lab operations, and facilities management. He also oversees environmental protection, occupational health, safety procedures, and quality systems.
Before joining CST in 2005, Craig spent nine years in venture-backed life science organizations, leading teams of scientists focused on technology development and drug discovery. He served as Senior Investigator, Group Leader, chemical genomics for ArQule, as Group Leader, cell biology for Akceli, and as Group Leader, microbiology for Scriptgen/ Anadys Pharmaceuticals.
Craig has a B.S. in molecular biology from the University of Wisconsin-Madison, and a Ph.D. in molecular biology from MIT. He also completed post-doctoral studies in immunobiology at Yale University. Craig has authored numerous peer-reviewed scientific articles and patents.